United States Value-Based Reimbursement Models for Cell and Gene Therapies Market
Global value‑based reimbursement models for cell and gene therapies market size was valued at USD 1.19 billion in 2025. Assuming the United States captures roughly 45 % of the worldwide spend on advanced therapeutics, the U.S. segment is estimated at USD 0.54 billion in 2025, projected to rise from USD 0.58 billion in 2026 to USD 1.04 billion by 2034, reflecting a CAGR of 8.9 % over the forecast horizon.
www.intelmarketresearch.com/united-states-value-based-reimbursement-models-for-cellgene-therapies-market-50003
Global value‑based reimbursement models for cell and gene therapies market size was valued at USD 1.19 billion in 2025. Assuming the United States captures roughly 45 % of the worldwide spend on advanced therapeutics, the U.S. segment is estimated at USD 0.54 billion in 2025, projected to rise from USD 0.58 billion in 2026 to USD 1.04 billion by 2034, reflecting a CAGR of 8.9 % over the forecast horizon.
www.intelmarketresearch.com/united-states-value-based-reimbursement-models-for-cellgene-therapies-market-50003
United States Value-Based Reimbursement Models for Cell and Gene Therapies Market
Global value‑based reimbursement models for cell and gene therapies market size was valued at USD 1.19 billion in 2025. Assuming the United States captures roughly 45 % of the worldwide spend on advanced therapeutics, the U.S. segment is estimated at USD 0.54 billion in 2025, projected to rise from USD 0.58 billion in 2026 to USD 1.04 billion by 2034, reflecting a CAGR of 8.9 % over the forecast horizon.
www.intelmarketresearch.com/united-states-value-based-reimbursement-models-for-cellgene-therapies-market-50003
0 Comentários
0 Compartilhamentos
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek